



Estrogen receptor signaling mechanisms

Nathalie Fuentes^a, Patricia Silveyra^{a,b,*}

^aDepartment of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, PA, United States

^bThe University of North Carolina at Chapel Hill, School of Nursing, Chapel Hill, NC, United States

*Corresponding author: e-mail address: patry@email.unc.edu

Contents

1. Estrogens: Definition and history	136
2. Estrogen biosynthesis	137
3. Estrogen metabolism	141
4. Physiological functions of estrogens	142
5. The estrogen receptors: History and discovery	142
6. Structural properties of estrogen receptors	143
7. Mechanisms of estrogen receptor signaling	146
8. Nuclear estrogen receptors: Direct genomic signaling	147
9. Nuclear estrogen receptors: Indirect genomic signaling	148
10. Membrane receptor: Indirect non-genomic signaling	150
11. Genomic and non-genomic signaling crosstalk	151
12. Estrogen receptor ligand independent signaling	152
13. Estrogen receptor coregulators and transcriptional control	153
14. Endogenous and exogenous estrogen receptors ligands	154
15. Discussion	157
Acknowledgments	158
References	158

Abstract

The primary female sex hormones, estrogens, are responsible for the control of functions of the female reproductive system, as well as the development of secondary sexual characteristics that appear during puberty and sexual maturity. Estrogens exert their actions by binding to specific receptors, the estrogen receptors (ERs), which in turn activate transcriptional processes and/or signaling events that result in the control of gene expression. These actions can be mediated by direct binding of estrogen receptor complexes to specific sequences in gene promoters (genomic effects), or by mechanisms that do not involve direct binding to DNA (non-genomic effects). Whether acting via direct nuclear effects, indirect non-nuclear actions, or a combination of both, the effects of estrogens on gene expression are controlled by highly regulated complex mechanisms. In this chapter, we summarize the knowledge gained in the past 60 years since the discovery of the estrogen receptors on the mechanisms governing

estrogen-mediated gene expression. We provide an overview of estrogen biosynthesis, and we describe the main mechanisms by which the female sex hormone controls gene transcription in different tissues and cell types. Specifically, we address the molecular events governing regulation of gene expression via the nuclear estrogen receptors (ER α , and ER β) and the membrane estrogen receptor (GPER1). We also describe mechanisms of cross-talk between signaling cascades activated by both nuclear and membrane estrogen receptors. Finally, we discuss natural compounds that are able to target specific estrogen receptors and their implications for human health and medical therapeutics.



1. Estrogens: Definition and history

The term “estrogens” refers to a group of female hormones, including estrone, estradiol, estriol, and estretrol (Fig. 1). Chemically, estrogens belong to the family of organic compounds known as steroids. As such, their core structure is composed of 17 carbon-carbon bonds arranged as four fused rings (three cyclohexane rings and a cyclopentane ring). All four estrogens contain 18 carbons (C₁₈H₂₄O₂) and are collectively known as C18 steroids. They consist of one benzene ring, a phenolic hydroxyl group, and a ketone group (estrone), or one (17 β -estradiol), two (estriol), or three (estretrol) hydroxyl groups.




Fig. 1 Chemical structures of endogenous estrogens. Estrone (E₁; orange), estradiol (E₂; blue), estriol (E₃; green) and estretrol (E₄; yellow).

Estrogens are primarily synthesized in the ovaries, but also in the adrenal glands and adipose tissue. They were discovered in the early 1900s, when ovarian extracts (“liquor folliculi”) from cattle and hogs were injected in rodents, and found to be effective in inducing sexual activity or “estrus” (Allen & Doisy, 1983). It was later determined that the hormone was produced by mature ovarian follicles, and that it was likely common to all female animals. The term estrogen derives from the Greek words *oistros* (frenzy, in heat) and *gennan* (to produce). As mentioned above, estrogens are a group of C18 hormones with similar chemical structures and function (Fig. 1). In addition, all four estrogens are able to bind to both nuclear and membrane estrogen receptors, with different affinity and strength of the response (Watson, Jeng, & Kochukov, 2008). However, the word estrogen is commonly used to refer to estradiol (or 17 β -estradiol), due to its physiological relevance and predominance during reproductive years. While females produce all estrogens throughout life, the hormones 16-hydroxyestradiol (estriol) and 15 α -hydroxyestriol (estretrol) are predominantly found during pregnancy, and estrone is usually found at higher levels during menopause (Samavat & Kurzer, 2015).


Estradiol, the predominant circulating estrogen in humans, it is mainly secreted by the granulosa cells of the ovarian follicles, and the corpora lutea. On the other hand, estretrol is synthesized exclusively by the fetal liver and reaches maternal circulation through the placenta (Coelingh Bennink, Holinka, Visser, & Coelingh Bennink, 2008; Holinka, Diczfalusy, & Coelingh Bennink, 2008). Estrone, which is produced by aromatization of androstenedione in extraglandular tissues, can be reversibly transformed to estradiol by the enzyme 17 β -hydroxysteroid dehydrogenase in peripheral tissues (Bulun, Zeitoun, Sasano, & Simpson, 1999; RYAN, 1959).



2. Estrogen biosynthesis

The main substrate for steroid hormone biosynthesis is dietary cholesterol, specifically low-density lipoprotein (LDL)-cholesterol (Carr, MacDonald, & Simpson, 1982). Through a process called steroidogenesis, cholesterol is converted to the 21-carbon (pregnanes, progestogens), 19-carbon (androstanes), and 18-carbon (estrans) steroid hormones in gonads, adrenal cortex, and adipose tissue (Miller, 2017). The main site of estrogen synthesis is the ovaries, and specifically the granulosa cells (Fig. 2).

The first step in the biosynthesis of steroid hormones is the translocation of cholesterol into the inner mitochondrial membrane, a process regulated



Theca cell

Granulosa cell

Fig. 2 Association of theca and granulosa cell in estrogen synthesis. The luteinizing hormone (LH) induces the production of androgens in theca cells. The follicle-stimulating hormone (FSH) stimulates granulosa cells via aromatization of androgens to estrogens and by using cholesterol to produce pregnenolone. The process occurs in the ovarian follicle, which is composed of granulosa cells, oocyte, basal lamina and theca cells. CREB, cyclic AMP response element binding protein; PKA, protein kinase A; LDL, low density lipoproteins; cAMP, cyclic adenosine monophosphate; STAR, steroid acute regulatory protein; P450c17, 17 α -hydroxysteroid dehydrogenase; 17 β HSD, 17 β -hydroxysteroid dehydrogenase.

by the steroidogenic acute regulatory protein STARD1 (also known as StAR), which is believed to act as a shuttle enzyme (Miller & Strauss, 1999). This is the rate-limiting step of steroidogenesis in all tissues. The expression of StAR is controlled by a mechanism involving binding of luteinizing hormone (LH) to its G protein-coupled receptor in the theca cells of the ovary and stimulation of adenylate cyclase, which catalyzes the production of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). The cAMP produced activates protein kinase A, which catalyzes phosphorylation of cAMP response element binding protein (CREB) leading to activation of transcription of StAR and other factors associated with steroid hormone production (Fig. 2). At the inner mitochondrial membrane, cholesterol is converted to pregnenolone by the enzyme P450_{scc}, or cholesterol side-chain cleavage enzyme, encoded by the CYP11A1 gene (Belfiore, Hawkins, Wiltbank, & Niswender, 1994). Pregnenolone then acts as a precursor for all steroid hormones (Fig. 3), and can diffuse between adjacent granulosa and theca cells of the ovary. The synthesis continues with the conversion of pregnenolone to androstenedione by the enzymes CYP17A1 (steroid 17- α -hydroxylase/17,20-lyase) and 3 β -HSD (3 β -hydroxysteroid dehydrogenase/ Δ^{5-4} isomerase), via dehydroepiandrosterone (DHEA). Androstenedione can be either converted




Fig. 3 Estrogen biosynthesis pathway. The estrogen biosynthetic pathway involves the conversion of cholesterol to progestogens, androgens and finally estrogens. The conversion of androgen to estrone (E1) and estradiol (E2) catalyzed by aromatase is the final step for synthesis of estrogen.

to other androgens, such as testosterone and dihydrotestosterone, or diffuse to the granulosa cells through the basal lamina (Fig. 2). At the granulosa cells, androstenedione is converted to estrone by the enzyme CYP19A1 (also known as aromatase). Estrone is then converted to estradiol by the enzyme 17 β -HSD (17 β -hydroxysteroid dehydrogenase). In the granulosa cells, the expression of both aromatase and 17 β -HSD is controlled by follicle stimulating hormone (FSH) stimulation. Interestingly, testosterone can be metabolized to estradiol and estrone by the action of aromatase in peripheral tissues, including adipose cells and bone (Simpson et al., 2002). Males also produce local estrogen by aromatization in cells of the reproductive tract, including Sertoli cells, Leydig cells, and mature spermatocytes. Overall, estrogens are normally produced by the ovaries and in smaller amounts by other tissues such as the liver, pancreas, adrenal glands, adipose tissue, and breast (Barakat, Oakley, Kim, Jin, & Ko, 2016). In specific physiological conditions, such as pregnancy, estrogen is also synthesized by the placenta. However, the biosynthesis of estrogen in non-gonadal sites follows rather unusual mechanisms, since these tissues are not able to generate C19 steroids from cholesterol. In these tissues, estrogen production is largely dependent on C19 steroids transported from other tissues and conversion by local CYP19A1 aromatase (Labrie et al., 1998; Nelson & Bulun, 2001).

Estradiol, the predominant circulating estrogen in humans, it is mainly secreted by the granulosa cells of the ovarian follicles, and the corpora lutea, by the mechanisms indicated above. On the other hand, estretrol is synthesized exclusively during pregnancy by the fetal liver and reaches maternal circulation through the placenta (Coelingh Bennink et al., 2008; Holinka et al., 2008). Estriol, which is also primarily synthesized during pregnancy, is almost exclusively produced by the placenta. To produce estriol, dietary cholesterol is converted to pregnenolone and progesterone in the placenta, and these steroids are further metabolized to DHEA and DHEA-sulfate (DHEA-S) in the fetal adrenal glands. DHEA-S is later hydroxylated to 16 α -OH-DHEA-S in the fetal liver by the action of the CYP3A7 enzyme, and transported back to the placenta where it is converted to 16 α -OH-DHEA by the steroid sulfatase. The enzyme 3 β -HSD1 converts 16 α -OH-DHEA into 16 α -OH-androstenedione, which is later aromatized to 16 α -OH-estrone. In the final step, 16 α -OH-estrone is converted to estriol by the 17 β -HSD enzyme, and secreted into maternal circulation (ITTRICH & NEUMANN, 1963; WILSON, ERIKSSON, & DICZFALUSY, 1964). In non-pregnant women, estriol is produced mainly in the liver by 16 α -hydroxylation of estradiol and

estrone by CYP enzymes (Samavat & Kurzer, 2015; Tsuchiya, Nakajima, & Yokoi, 2005). Finally, estrone is mainly produced during menopause by aromatization of androstenedione in extra-glandular tissues, where it can act locally as a paracrine or intracrine factor (Simpson, 2003). Estrone can also be transformed to estradiol by the enzyme 17 β -hydroxysteroid dehydrogenase in peripheral tissues, including adipose and breast tissue, vascular endothelium, smooth muscle cells, brain tissue, and bone cells, where it is metabolized or enters the circulation in small quantities (Bulun et al., 1999; RYAN, 1959; Simpson, 2003).



3. Estrogen metabolism

Physiologically, the metabolic conversion of estrogens allows their excretion from the body via urine, feces, and/or bile, along with the production of estrogen analogs, which have been shown to present antiproliferative effects (Tsuchiya et al., 2005). In target cells, there are different pathways capable of metabolizing estradiol and estrone. Members of the cytochrome P450 superfamily of enzymes (CYP1A1, CYP1B1, and CYP1A2) catalyze hydroxylation of estrone and estradiol at positions C2, C4 and C16. Due to the high expression of these enzymes in the liver, a large proportion of estrogen metabolism occurs in this tissue, although CYP1B1 is also expressed in target tissues such as mammary gland, uterus, kidney, brain, and pituitary gland, where estradiol and estrone can also be metabolized. Estradiol hydroxylation is followed by conversions to 2-hydroxyestrone, 4-hydroxyestrone, 2-hydroxyestradiol, 4-hydroxyestradiol, and 16 α -hydroxyestrone, which are also known as catechol estrogens, due to their presence of pharmacological properties of both catecholamines and estrogens. The hydroxylation of estradiol or 16 α -hydroxyestrone forms estriol. In addition, catechol estrogens can be methylated via the catechol-O-methyltransferase (COMT) enzyme to methoxy estrogens (Samavat & Kurzer, 2015). These compounds have gained significant attention due to their little estrogenic effects, antiproliferative properties, and ability to control estrogen synthesis (Purohit & Reed, 2002; Purohit et al., 2006). Moreover, catechol estrogens can also be conjugated by estrogen sulfotransferases and UDP-glucuronyltransferases (Cheng et al., 1998; Garbacz, Jiang, & Xie, 2017). In a conjugation reaction, hormones become water soluble and excreted from the body (Lakhani, Venitz, Figg, & Sparreboom, 2003).



4. Physiological functions of estrogens

Estrogens are sex steroid hormones, and as such display a broad spectrum of physiological functions. These include regulation of the menstrual cycle and reproduction, bone density, brain function, cholesterol mobilization, development of breast tissue and sexual organs, and control of inflammation (Liang & Shang, 2013). While estrogens play diverse roles in normal male and female physiology, in certain physiological situations they can play similar roles in both sexes (Simpson et al., 2005). In females, estrogens are responsible for primary and secondary sexual characteristics. Estradiol promotes epithelial cell proliferation in the uterine endometrium and mammary glands starting in puberty (Gruber, Tschugguel, Schneeberger, & Huber, 2002; Koos, 2011; Simpson et al., 2005). During pregnancy, estrogens produced by the placenta help prepare the mammary gland for milk production (Voogt, 1978). On the other hand, lower levels of estrogens produced in men are essential for functions including sperm maturation, erectile function and maintenance of a healthy libido (Schulster, Bernie, & Ramasamy, 2016). It is important to mention here that all the estrogenic physiological functions previously described are mediated by estrogen receptors, which we describe in the next sections.



5. The estrogen receptors: History and discovery

In 1958, Elwood Jensen discovered the estrogen receptor, the first receptor ever encountered for any hormone, by showing that reproductive female tissues were able to uptake estrogen from the circulation by binding to proteins. He later demonstrated that estrogen-bound receptors were able to migrate to the nucleus, where they could stimulate gene transcription (Jensen et al., 1967; Jensen et al., 1968). More than 20 years later, the first human estrogen receptor (known today as ER α) was cloned using RNA from the human breast cancer cell line MCF-7 (Green et al., 1986; Greene et al., 1986). Similarly, the second estrogen receptor (known today as ER β) was described 10 years later by the research team lead by Dr. Jan-Ake Gustafsson (Kuiper, Enmark, Peltö-Huikko, Nilsson, & Gustafsson, 1996). Gustafsson's lab discovered that a newly identified protein that was mainly expressed in the secretory epithelial cells of the prostate and in the granulosa cells of the ovary, shared a high degree of

homology with the ER α (DNA-binding domain, 95%; ligand-binding domain, 55%). As a result of these similarities, the team suggested for the protein be named ER β .

More recently, a new type of estrogen binding protein was discovered in target cells: The G Protein-Coupled Estrogen Receptor GPER1, or membrane estrogen receptor. Unlike the nuclear estrogen receptors ER α and ER β , which were isolated by traditional biochemical approaches, GPER1 was identified by molecular cloning methods (Filardo & Thomas, 2012). Almost two decades ago, several research laboratories had reported the isolation of a G Protein-Coupled Receptor homolog, which was ascribed the orphan term GPR30 (Carmeci, Thompson, Ring, Francke, & Weigel, 1997; Feng & Gregor, 1997; Kvingedal & Smeland, 1997; O'Dowd et al., 1998; Owman, Blay, Nilsson, & Lolait, 1996; Takada, Kato, Kondo, Korenaga, & Ando, 1997). It was assumed that the ligand for GPR30 was a hormone or chemotactic peptide due to its structural similarities to the receptors for angiotensin II and other peptides such as interleukin-8, monocyte chemotactic proteins, and complement factors (Filardo & Thomas, 2012). However, after screening of multiple chemotactic peptides and factors, no molecules with binding affinities to GPR30 were found, the receptor continued to be classified as orphan (Feng & Gregor, 1997). However, in the year 2000, a research team was able to show that fast estrogen-mediated activation of extracellular signal-regulated kinases (ERKs) was dependent on GPR30 (Filardo, Quinn, Bland, & Frackelton, 2000). Five years later, this and other groups were able to demonstrate direct binding of 17 β -estradiol to GPR30 in GPR30-transfected cells and breast cancer cell lines (Revankar, Cimino, Sklar, Arterburn, & Prossnitz, 2005; Thomas, Pang, Filardo, & Dong, 2005). Finally, in 2007 GPR30 was officially named G protein-coupled estrogen receptor 1 (also known as GPER or GPER1), and its role in mediating fast responses to estrogens and overall physiological and pathological processes has been studied extensively in human and animal models (Boonyaratanakornkit & Edwards, 2007; Filardo et al., 2007; Molina, Figueroa, Bhoola, & Ehrenfeld, 2017; Prossnitz & Barton, 2014; Sharma & Prossnitz, 2016).



6. Structural properties of estrogen receptors

The full-length size of ER α is 595 amino acids and 67 kDa. ER β is 530 amino acids in length and 59 kDa. The main difference between the two proteins is that ER β has a shorter amino terminal domain than ER α (Fig. 4).




Fig. 4 Structural organization of estrogen receptors. Structural domains of estrogen receptor α (ER α) (595 aa) and ER β (530 aa) are labeled A-F. Both receptors have six different structural and functional domains: N- terminal (NTD, A/B domains, AF-1), DNA binding domain (DBD, C domain), the hinge (D domain), the C-terminal region containing the ligand binding domain (LBD, E/F domain, AF-2).

As members of the nuclear hormone receptors superfamily of transcription regulators, the structures of the estrogen receptors ER α and ER β are composed of various functional domains and have several structural regions in common (Schwabe & Teichmann, 2004). The principal functional domains are termed A/B, C, D, and E/F, and are present in both receptor full-length structures (Fig. 4). The A/B region represents the amino-terminal domain (NTD), which is involved in gene transcription transactivation, and contains a zinc-finger that mediates binding to target sequences. The C region corresponds to the DNA binding domain (DBD), which contributes to estrogen receptor dimerization and binding to specific sequences in the chromatin. These canonical sequences known collectively as estrogen response elements (ERE) (Scheidereit et al., 1986; Truss & Beato, 1993). The D domain is a hinge region that connects the C and E domains, and is able to bind to chaperone proteins. This region also contains the nuclear localization signal, that is unmasked upon estrogen binding, allowing for the receptor-ligand complexes to translocate to the nucleus. In the carboxy-terminal E/F region, also known as the ligand binding domain, contains the estrogen binding area, along with binding sites for coactivators and corepressors. Finally, two additional regulators of the estrogen receptor transcriptional activity known as activation function (AF) domains AF1 and AF2, are located within the NTD and DBD, respectively (Kumar et al., 2011). The mechanisms of transcriptional regulation mediated by these receptors appear to involve a synergistic effect of AF1 and AF2 (Tora et al., 1989). Contrarily to AF2, AF1 does not require binding to hormones or steroids to be activated (Kumar et al., 2011).

In humans, the ER α is encoded by the gene ESR1, located on chromosome 6, locus 6q25.1 (Gosden, Middleton, & Rout, 1986). In addition to




Fig. 5 Estrogen receptor alpha (ER α) isoforms. The domain organization of the full-length 595 amino acid ER α (67kDa), and truncated shorter isoforms (62kDa, 53kDa, 46kDa, 45kDa, and 36kDa) resulting from alternative splicing and/or alternate translation start sites are illustrated. Protein domains are labeled as A to F with numbering denoting amino acid sequence number based on the full-length protein (595 aa). ER α domains: N-terminal (NTD, A/B domains, AF-1), DNA binding domain (DBD, C domain), hinge (D) domain, and C-terminal region containing the ligand binding domain (LBD, E/F domain, AF-2).

the full-length ER α isoform (66kDa), several shorter isoforms (36kDa, 46kDa) have been identified as a result of the presence of alternate start codons, or as products of alternative splicing (Fig. 5). Some of these shorter isoforms do not have the NTD and thus lack the AF-1 domain. Therefore, they cannot activate transcription. Instead, they are able to form heterodimers with the full-length ER α and inhibit its ability to control transcriptional. The shorter isoform, ER α -36, lacks both AF-1 and AF-2 transcriptional activation domains, and it has been shown to exert membrane-initiated signaling events upon binding to estradiol, estriol, and estetrol (Gu et al., 2014), as well as to mediate GPER1 responses (Arnal et al., 2017; Romano & Gorelick, 2018).

On the other hand, ER β is encoded by the ESR2 gene located in chromosome 14 (14q23–24), and has five known isoforms (Enmark et al., 1997) (Fig. 6). The main difference between the full-length ER β and the shorter ER β isoforms is on the C-terminal LBD. Therefore, ER β isoforms that have no transcriptional activity can also suppress ER α signaling by dimerizing with ER α (Vrtačnik, Ostanek, Mencej-Bedrač, & Marc, 2014).

Finally, the gene coding for the membrane receptor GPER1 is located in chromosome 7 (locus 7p22.3). In terms of structure, GPER1 does not share similarities with ER α or ER β . As a typical G protein coupled receptor, its structure consists of 7 transmembrane α -helical regions, 4 extracellular segments, and 4 cytosolic segments (Barton et al., 2018). This receptor




Fig. 6 Estrogen receptor beta (ERβ) isoforms. The domain organization of the full-length 530 amino acid ERβ (59 kDa), truncated shorter isoforms (54 kDa, 49 kDa, and 44 kDa), and elongated isoform (61 kDa), resulting from alternative splicing and/or alternate translation start sites are illustrated. Protein domains are labeled as A to F with numbering denoting amino acid sequence number based on the full-length protein (595 aa). ERβ domains: N-terminal (NTD, A/B domains, AF-1), DNA binding domain (DBD, C domain), hinge (D) domain, and C-terminal region containing the ligand binding domain (LBD, E/F domain, AF-2).

has low binding affinity (17β-estradiol) when compared to other estrogen receptors (Prossnitz & Barton, 2014). However, this may be important as GPER1 is accountable for rapid responses to estrogen, and activation of intracellular signaling cascades mediated by second messengers (Filardo & Thomas, 2012).

7. Mechanisms of estrogen receptor signaling

As a steroid hormone, estrogen can enter the plasma membrane and interact with intracellular ERα and ERβ to exert direct effects by binding to DNA sequences. Alternatively, estrogen can activate intracellular signaling cascades via interaction with the GPER1 and/or ERα and ERβ. Due to differences in the cellular and molecular events leading to gene expression regulation in which estrogen-receptor complexes can either bind directly or indirectly to DNA, estrogen-mediated signaling events can be divided into genomic and non-genomic. Genomic effects are those involving migration of the estrogen-receptor complexes to the cell nucleus, and direct interaction with chromatin at specific DNA sequences known as estrogen response elements (EREs). While EREs have been identified in several gene promoters and regulatory regions, it has been reported that more than one third of human genes regulated by estrogen receptors do not contain ERE sequence elements (O'Lone, Frith, Karlsson, & Hansen, 2004). On the other

hand, non-genomic effects involve indirect regulation of gene expression through a variety of intracellular signaling events. The known mechanisms for genomic and non-genomic control of gene expression by estrogens are described below.



8. Nuclear estrogen receptors: Direct genomic signaling

Direct genomic signaling is known as the classical mechanism of estrogen signaling. In this process, the nuclear estrogen receptors ER α and ER β act as ligand-activated transcription factors (Marino, Galluzzo, & Ascenzi, 2006; O'Malley, 2005). Upon binding of estradiol to ER α or ER β in the cytoplasm, a conformational change occurs inducing receptor dimerization (Le Dily & Beato, 2018(Fig. 7)). This complex is then translocated to the nucleus, where it binds to the chromatin at ERE sequences, enhancer regions within or close to promoters, and/or 3'-untranslated regions of target genes (Klinge, 2001).

Recent advances in computational biology have facilitated the identification of EREs in many gene promoters, and allowed prediction of genes regulated by estrogen and other hormones in the genomes of many species (Bajic et al., 2003; Bourdeau et al., 2004). A recent genome-wide screening study identified over 70,000 EREs in the human and mouse genomes (Bourdeau et al., 2004). Interestingly, 17,000 of these EREs were located near mRNA transcriptional start sites, and only 660 were conserved sites. The efficacy of this computational approach was further supported by functional validation of estrogen receptor interaction sites (Carroll & Brown, 2006). While these elements share a high degree of sequence similarity, it is important to recognize that the intrinsic sequence composition of the EREs can alter the affinity of the receptor to bind DNA. For example, ER α has a high binding affinity for the canonical ERE sequence located within the vitellogenin A2 gene, but with less affinity for the EREs located in the oxytocin gene (Sausville, Carney, & Battey, 1985). This moderately explains why differences in ERE sequences, such as those resulting from inter-individual gene variability or mutations, can affect the activation of gene expression (Loven, Wood, & Nardulli, 2001; Yi et al., 2002). In addition, specific ERE sequences can cause allosteric changes in the receptor's structure, and thus alter the ability of the complex to recruit coactivators and transcription factors that may contribute to ER biological activity (Hall, McDonnell, & Korach, 2002; Yaşar, Ayaz, User, Güpür, & Muyan, 2017).




Fig. 7 Genomic and non-genomic estrogen signaling pathways. There are different estrogen-mediated signaling mechanisms. (1) Direct genomic signaling: estrogen binds to ERs. The complex dimerizes and translocate to the nucleus inducing transcriptional changes in estrogen-responsive genes with or without EREs. (2) Indirect genomic signaling: the membrane bound receptor induces cytoplasmic events such as modulation of membrane-based ion channels, second-messenger cascades and transcription factors. (3) ER-independent: estrogen exerts antioxidant effects in an ER-independent manner. (4) Estrogen independent: ligand-independent genomic events.



9. Nuclear estrogen receptors: Indirect genomic signaling

As mentioned earlier, the transcription of several genes that do not contain EREs in their promoter regions can also be regulated by estradiol, without direct binding of the estrogen receptors to the DNA. According to the most recent reports, an estimated 35% of genes targeted by estrogen lack ERE-like sequences (Marino et al., 2006; Vrtačnik et al., 2014). In these, the mechanisms by which estrogen affects gene expression are collectively

known as “indirect genomic signaling” or “transcriptional cross-talk”, and are based on activation of gene expression by estrogen receptors not binding DNA directly. Rather, the estrogen receptor complexes act through protein-protein interactions with other transcription factors and response elements (Aranda & Pascual, 2001; Göttlicher, Heck, & Herrlich, 1998). In this way, estrogens indirect signaling influences activation or suppression of target gene expression.

An important mediator of indirect genomic signaling is the stimulating protein-1 (Sp-1). Binding of this transcription factor to promoter regions at GC-rich sites is enhanced by the presence of estrogen receptors (Bajic et al., 2003; O’Lone et al., 2004). Examples of genes induced by estrogen via the Sp-1 mechanism are: low-density lipoprotein (LDL) receptor (Li, Briggs, Ahlborn, Kraemer, & Liu, 2001), progesterone receptor B (O’Lone et al., 2004), endothelial nitric oxide synthase (eNOS) (Chambliss & Shaul, 2002), GATA binding protein 1 (GATA1), signal transducer and activator of transcription 5 (STAT5) (Björnström & Sjöberg, 2005), and the retinoic acid receptor-1 α genes (Sun, Porter, & Safe, 1998). A few studies have shown that ER α can also interact with the c-rel subunit of the nuclear factor- κ B (NF- κ B) complex, preventing NF- κ B from binding to cytokine genes promoters (Galien & Garcia, 1997; Kalaitzidis & Gilmore, 2005). Moreover, ER α can also interact with other transcriptional modulators such as the activating transcription factor (ATF)-2, c-jun, the ATF-1/cAMP response element binding protein (ATF-1/CREB), and the nuclear transcription factor-Y (NF-Y) (O’Lone et al., 2004).

The nuclear estrogen receptors also induce the expression of genes containing the activator protein-1 (AP-1) sites through protein-protein interactions (Gaub, Bellard, Scheuer, Chambon, & Sassone-Corsi, 1990). AP-1 is a transcription factor that regulates key cellular processes such as cell differentiation, proliferation, and apoptosis. The structure of AP-1 consists of a heterodimer composed of proteins belonging to the c-Fos, c-Jun, ATF, and the Jun dimerization partners (JDP) families (Piu, Aronheim, Katz, & Karin, 2001). The ER α also interacts with c-Fos and c-Jun at these binding regions (O’Lone et al., 2004). Some examples of genes induced by ER α via the AP-1 mechanism are insulin-like growth factor-1 (IGF1), collagenase, IGF1-receptor, ovalbumin, and cyclin D1 (Fujimoto, Honda, & Kitamura, 2004; Marino, Acconcia, Bresciani, Weisz, & Trentalance, 2002). However, previous studies have shown that ER α and ER β signal in different ways depending on the ligand and response elements present at the AP-1 sites. In fact, 17 β -estradiol activates AP-1-dependent transcription via ER α ,

whereas ER β inhibits this mechanism (Paech et al., 1997). Likewise, 17 β -estradiol binding to ER α induces transcription when linked to Sp-1 in GC-rich regions, but not when 17 β -estradiol is bound to ER β . One example of this is the contrasting action of ER α and ER β on the control of cyclin D1 gene expression (Liu et al., 2002), where estrogen-bound ER β suppresses cyclin D1 expression (Marino et al., 2006) and blocks ER α -mediated production when both receptors are present (Acconcia et al., 2005; Matthews & Gustafsson, 2003). The diversity of mechanisms of transcriptional regulation in different cells by the two estrogen receptors and their interactions with local transcription factors may explain the differences observed in tissue specific biologic responses to estrogens.



10. Membrane receptor: Indirect non-genomic signaling

As mentioned above, not all estrogen responses fit the classical genomic model of steroid action. The observation of excessively fast estrogen-induced biological responses led to the development of the hypothesis that estrogen could be acting by mechanisms not involving direct target gene transcription and protein synthesis, and the subsequent discovery of the GPER1 (Prossnitz & Barton, 2011). Non-genomic actions of estrogen often involve activation of signal-transduction mechanisms with the subsequent production of intracellular second messengers, cAMP regulation and protein-kinase activation of signaling cascades that result in indirect changes in gene expression (Lösel & Wehling, 2003) (Fig. 7). The protein-kinase cascades can be classified into four major ones: (1) the phospholipase C (PLC)/protein kinase C (PKCs) pathway (Marino, Pallottini, & Trentalance, 1998), (2) the Ras/Raf/MAPK cascade (Dos Santos et al., 2002; Watters, Campbell, Cunningham, Krebs, & Dorsa, 1997), (3) the phosphatidyl inositol 3 kinase (PI3K)/Akt kinase cascade (Marino, Acconcia, & Trentalance, 2003), and (4) the cAMP/protein kinase A (PKA) signaling pathway (Gu & Moss, 1996; Picotto, Massheimer, & Boland, 1996). Additionally, GPER1 binding to estrogens promotes estrogen-dependent activation of adenylyl cyclase and epidermal growth factor receptor (EGFR). Subsequent phosphorylation of transcription factors by the protein kinases mentioned above can alter their function and ability to bind to genomic sequences to affect gene expression. Examples of transcription factors that are affected by these signaling mechanisms include: Elk-1, CREB, CCAAT-enhancer-binding protein beta (C/EBP β), the NF- κ B complex, and the signal transducer and activator of transcription (STAT) family (Cavalcanti, Lucas, Lazari, & Porto, 2015;

Fox, Andrade, & Shupnik, 2009; Furth, 2014; Kousteni et al., 2003; Laliotis et al., 2013; Ozes et al., 1999; Romashkova & Makarov, 1999). Thus, by activating these non-genomic to genomic mechanisms, the estrogen receptors ER α and ER β indirectly regulate gene transcription at alternative DNA response elements, in addition to the abovementioned genomic effects involving direct binding to EREs (Fig. 7). Another interesting fact is that both ER α and ER β are also targets for phosphorylation by protein kinases including MAPKs, indicating that non-genomic actions of estrogens may also involve self-regulation of receptor expression (de Leeuw, Neefjes, & Michalides, 2011; Kato et al., 1995).

Both the membrane bound estrogen receptor GPER1, and some variants of the ER α and ER β have been associated to non-genomic estrogen signaling (Barton et al., 2018; Filardo & Thomas, 2012). It has been suggested that non-genomic actions of the ER α and ER β could be mediated through a sub-population of receptors that located at the cell membrane and can activate intracellular signaling cascades (Razandi, Pedram, Merchenthaler, Greene, & Levin, 2004). At the cell membrane, the ER α and ER β can interact with scaffold proteins such as caveolin-1 and MNAR/PELP-1 (modulator of non-genomic activity of estrogen receptor) (Chambliss et al., 2000; Cheskis et al., 2008; Shaul & Anderson, 1998). By proximity, the ER α and ER β also interact with G proteins, various membrane receptors (e.g., tyrosine kinase, insulin growth factor 1, and epidermal growth factor receptors), and signaling molecules including ras, Src and PI3 kinases, ErbB2 (HER-2/neu) and Shc that are located at or near the membrane (Boonyaratankornkit, 2011; Li et al., 2007; Migliaccio et al., 1996; Song et al., 2010; Song, Zhang, Chen, Bao, & Santen, 2007; Song, Zhang, & Santen, 2005). Interactions with these molecules promotes intracellular activation of mitogen activated protein kinases (MAPK) and protein kinase B (Akt) signaling pathways that can affect transcriptional regulation (Li et al., 2010). While there is no clear consensus among the experts in the field about binding of ER α and ER β to the plasma membrane, it appears that the mechanisms described above are cell-type specific and activated under certain physiological events, and by specific receptor variants (Li, Haynes, & Bender, 2003).



11. Genomic and non-genomic signaling crosstalk

As exemplified in the previous sections, it is evident that the mechanisms of action of estrogen in the various cell targets represent a combination of complex multifactorial processes. Besides the independent genomic and

non-genomic pathways described above, many authors have proposed the existence of additional convergent pathways involving both genomic and non-genomic factors that result in regulation of gene transcription (Björnström & Sjöberg, 2005; Silva, Kabil, & Kortenkamp, 2010; Vrtačnik et al., 2014). Two mechanisms of “cross-talk” have been described, and involve protein-protein interactions of components of both pathways. In one mechanism, estrogen-bound nuclear estrogen receptor complexes are dimerized and translocated to the nucleus, where they bind to phosphorylated transcription factors resulting from GPER1-mediated signaling. The complexes then bind to either ERE sequences via the nuclear estrogen receptors, or to AP-1, STATs, ATF-2/c-Jun, Sp1, and/or NF- κ B cognate DNA binding sites (Björnström & Sjöberg, 2005). In the second mechanism, interaction of GPER1 and ER α and ER β located at the plasma membrane activate protein kinase cascades that result in phosphorylation of AP-1, STATs, Elk-1, CREB, and NF- κ B, and other transcription factors, as well as estrogen receptors themselves, that can then interact with DNA sequences to regulate transcription (Björnström & Sjöberg, 2005). Thus, convergence of the two classical estrogen receptor regulation pathways can result in enhanced transcriptional activity in specific tissues and physiological processes.



12. Estrogen receptor ligand independent signaling

An interesting phenomenon observed in many cells is that estrogen receptors can actually be activated in the absence of estrogens or other receptor agonists (Bennesch & Picard, 2015; Maggi, 2011; Vrtačnik et al., 2014). This ligand-independent estrogen receptor activation is mainly triggered by phosphorylation on specific residues (e.g., serine and tyrosine) in the receptors themselves, or their association with coregulators (described below). This independent mechanism requires the action of regulatory molecules necessary for phosphorylation, such as protein kinase A (PKA), protein kinase C (PKC), MAPK phosphorylation cascade components, as well as inflammatory cytokines (e.g., interleukin-2), cell adhesion molecules (e.g., heregulin), cell cycle regulators (e.g., RAS p21 protein activator cyclins A and D1), and peptide growth factors including EGF, insulin, IGF1, and transforming growth factor beta (TGF β) (Nilsson et al., 2001).



13. Estrogen receptor coregulators and transcriptional control

In addition to the regulatory pathways described above, the cell also expresses a battery of coregulators that can either enhance or decrease transcriptional activity of steroid hormone receptors. These are called estrogen receptor coactivators and corepressors, respectively. Coregulators are involved in many steps of the gene expression process, including chromatin modification and remodeling, transcription initiation, elongation of RNA chains, mRNA splicing, mRNA translation, miRNA processing, and degradation of the activated NR–coregulator complexes (Lonard & O'malley, 2007). Currently, there are hundreds of coregulators of nuclear receptors described that play a key role in promoting gene expression and transcriptional activity. Coregulators are a dynamic group of proteins able to act as integrators of signals from steroid hormones, and have been linked to many diseases affected by sex hormones, such as cancer (Lonard & O'Malley, 2006). One of the first coregulators of ER α , known as steroid receptor coactivator (SRC-1), was identified in 1995 (Oñate, Tsai, Tsai, & O'Malley, 1995). Since then, many additional coregulators have been discovered for ER α , although very few are known for ER β (Lonard & O'Malley, 2006). Coregulators for ER α comprise members of the steroid receptor coactivator (SRC)/p160 group, the histone acetyltransferase cAMP responsive element binding protein (CREB)–binding protein (CBP)/p300, ATP-dependent chromatin remodeling complexes like SWI/SNF, E3 ubiquitin–protein ligases, and steroid RNA activator (SRA) (Lonard & O'Malley, 2006; Manavathi, Samanthapudi, & Gajulapalli, 2014). Therefore, as indicated above, even though both nuclear estrogen receptors are able to use estradiol as their physiological ligand, they exert multiple effects and functions in different cells and tissues that are mediated by several intermediaries and differential utilization of coregulators (Manavathi et al., 2014).

The mechanisms by which coregulators control the actions of estrogen receptors are still a topic of ongoing research. From studies in cancer cells, we have learned that a large group of coregulators have specific structural motifs that than affect their contact with ER ligand-binding domains (Heery, Kalkhoven, Hoare, & Parker, 1997). The specific motifs are called NR boxes or LXXLL motifs (X, any amino acid; L, leucine). On the other hand, we know that corepressors block ER-mediated gene transcription via

(1) direct interaction with unbound estrogen receptors; (2) using their corepressor nuclear receptor box; (3) competing with coactivators (Hu & Lazar, 1999). It has also been reported that the concentration of several coregulators depends on estrogen induced-transcriptional regulation via the estrogen receptors (Mishra, Balasenthil, Nguyen, & Vadlamudi, 2004). Additionally, several post-translational modifications such as phosphorylation, methylation, ubiquitination, SUMOylation, and acetylation can impact the action of coregulators targeting gene expression (Han, Lonard, & O'Malley, 2009; Lonard & O'malley, 2007; O'Malley & McKenna, 2008).



14. Endogenous and exogenous estrogen receptors ligands

Apart from the estrogens that are naturally produced by gonadal and other tissues in the body, there is a diverse variety of organic and inorganic molecules that are able to recognize the estrogen receptors ligand-binding domains in a precise manner (Table 1). Most of these ligands display higher selectivity toward ER α , however, several selective compounds for ER β have recently been described (Farooq, 2015). There are five main classes of ER ligands: endoestrogens, phytoestrogens, xenoestrogens, selective estrogen receptor modulators (SERMs) and metalloestrogens.

Endoestrogens are physiological estrogens that are endogenously produced by the body. Most endoestrogens (i.e., estradiol, estriol, estretrol, and estrone) were previously discussed in the chapter. Briefly, endoestrogens are steroidal compounds produced from cholesterol in the male and female gonads and other organs (Farooq, 2015). In contrast, phytoestrogens are non-steroidal compounds produced by plants. There are three known groups of phytoestrogens: isoflavones, coumestans, and lignans (Basu & Maier, 2018). Because phytoestrogens are chemically and structurally similar to estradiol, they can participate in both estrogenic and antiestrogenic effects through activation or blocking of the estrogen receptor ligand-binding domains (Turner, Agatonovic-Kustrin, & Glass, 2007). Interestingly, the phytoestrogens genistein, coumestrol, and liquiritigenin have been reported to display more affinity toward ER β than to ER α , but the implications of these differences remain unknown (Kuiper et al., 1998; Manas, Xu, Unwalla, & Somers, 2004; Mersereau et al., 2008; Nilsson, Kuiper, & Gustafsson, 1998).

Xenoestrogens are another group of ligands that comprise an extensive variety of non-natural synthetic chemical compounds with estrogenic effects.

Table 1 Types of estrogen receptor ligands.

Endoestrogens	Phytoestrogens	Xenoestrogens	SERMs	Metalloestrogens
Estrone 17 β -estradiol estrinol estretrol	Isoflavones: genistein, daidzein, formononetin, glycitein Coumestans: coumestrol, repensol, trifoliol Lignans: lariciresinol, matiresinol, pinoresinol, secoisolariciresinol, podophyllotoxin, steganacin	Medicinal drugs: diethylstilbestrol, ethinyl estradiol Food additives: butylated hydroxyanisole, erythrosine Body cosmetics: 4-methylbenzylidene camphor, methylparaben, ethylparaben, propylparaben Environmental pesticides: atrazine, dichlorodiphenyldichloroethylene, dichlorodiphenyltrichloroethane, methoxychlor, dieldrin, endosulfan, heptachlor, lindane Industrial chemicals: bisphenol A, nonylphenol, monochlorobiphenyl and dichlorobiphenyl, di-2-ethylhexyl phthalate, diisodecyl phthalate, diisononyl phthalate	Tamoxifen Clomifene Toremifene Raloxifene Ormeloxifene	Cations: aluminum (Al^{3+}), antimony (Sb^{3+}), barium (Ba^{2+}), cadmium (Cd^{2+}), chromium (Cr^{2+}), cobalt (Co^{2+}), copper (Cu^{2+}), lead (Pb^{2+}), mercury (Hg^{2+}), nickel (Ni^{2+}) Anions: arsenite (AsO_3^{3-}), selenite (SeO_3^{2-}), vanadate (VO_4^{3-})

The family of xenoestrogens can be divided into five major types: medicinal drugs, food additives, body cosmetics, environmental pesticides, and industrial chemicals (Farooq, 2015). Drugs such as diethylstilbestrol (DES) and ethinyl estradiol were specifically synthesized to mimic the action of endoestrogens, and have been extensively to treat many conditions in women (Gennari, Merlotti, Valleggi, Martini, & Nuti, 2007; Maximov, Lee, & Jordan, 2013). However, it has been found that these compounds can affect cellular and molecular processes leading to severe effects on health, and their use in medical therapeutics remains controversial (Aravindakshan, Gregory, Marcogliese, Fournier, & Cyr, 2004; Aravindakshan et al., 2004; Arukwe, Celius, Walther, & Goksøyr, 2000; Christin et al., 2004; Golden et al., 1998; Iorga et al., 2017; Vajda et al., 2008; Williams, Lech, & Buhler, 1998). In the past few years, a wealth of evidence has been accumulated demonstrating that estrogens regulate many facets of the inflammatory response and the immune system via complex molecular mechanisms that are also sex dependent (Khan & Ansar Ahmed, 2015). It is now plausible that any immune cell that expresses estrogen receptors can potentially respond to ligand binding in a context-dependent manner, which will affect the outcome of the overall immune response. Thus, given the known spatial and temporal expression of the estrogen receptors, it is important to consider this aspect when designing potential therapeutic therapies targeting the estrogen receptor signaling pathways (Arnal et al., 2017). Additionally, precise timing of treatment initiation and duration may be required to determine the true efficacy of estrogen treatment (Burns & Korach, 2012; Hamilton, Hewitt, Arao, & Korach, 2017).

The selective estrogen receptor modulators (SERMs) are another type of estrogen receptor ligands. The main difference between SERMs and xenoestrogens relies on the fact that SERMs present functional duality and are able to act both as agonists and antagonists of the estrogen receptors in different tissues (Martinkovich, Shah, Planey, & Arnott, 2014; Shang & Brown, 2002; Smith & O'Malley, 2004). At the molecular level, SERMs employ their antagonistic actions by competing with estradiol for binding to an inner hydrophobic pocket within the ligand-binding domain of ER α (Bourguet, Germain, & Gronemeyer, 2000; Shiao et al., 1998; Wärnmark et al., 2002). Binding of this estradiol agonist induces a conformational change in the LBD that results in sealing the ligand binding pocket. Some of the most important SERMs include tamoxifen, raloxifene, clomifene, ormeloxifene, and toremifene (Farooq, 2015). One of the most used SERMs in the treatment of breast cancer, tamoxifen, acts as an antagonist

in breast tissue, but as an agonist in the uterus. Therefore, while tamoxifen is often the selected treatment for ER-positive breast cancer, it can also stimulate endometrial cell growth leading to uterine cancer (Hu, Hilakivi-Clarke, & Clarke, 2015). While most SERMs are mainly selective for ER α , there are a few synthetic steroidal analogs that can regulate the actions of ER β , or both receptors (Blizzard et al., 2007; Blizzard et al., 2006; Blizzard et al., 2007; Papapetropoulos, 2007).

Finally, in addition to the organic ligands mentioned above, there are also inorganic compounds in the form of heavy metal ions that present estrogenic activity. These are collectively known as metalloestrogens. Examples of these include: aluminum (Al³⁺), antimony (Sb³⁺), barium (Ba²⁺), cadmium (Cd²⁺), chromium (Cr²⁺), cobalt (Co²⁺), copper (Cu²⁺), lead (Pb²⁺), mercury (Hg²⁺), nickel (Ni²⁺), arsenite (AsO₃³⁻), selenite (SeO₃²⁻) and vanadate (VO₄³⁻) (Farooq, 2015). Studies have shown that these metalloestrogens are able to coordinate to specific amino acid residues within the ligand-binding domain of the nuclear estrogen receptors, thus blocking binding of estradiol in a non-competitive manner (Stoica, Katzenellenbogen, & Martin, 2000; Stoica, Pentecost, & Martin, 2000a, 2000b).



15. Discussion

Estrogen receptors regulate a multitude of biological and physiological processes. These are tightly controlled by complex mechanisms involving either genomic nuclear direct binding to specific DNA sequences, or activation of intracellular cascades resulting in non-genomic control of transcription. Over the past 60 years since the discovery of the first nuclear estrogen receptors, and the almost 20 years since the discovery of the membrane receptor, multiple mechanisms of action have been discovered and characterized. These involve a multitude of intracellular kinases, transcription and growth factors, membrane receptors, coregulators, and natural and synthetic ligands. The information obtained in these studies has helped in the design of therapeutic strategies for diseases involving the estrogen receptors such as many cancers, as well as in the treatment of endocrine conditions affecting fertility and resulting from menopause. While there are still many diseases for which estrogens have been implicated but the role of their receptors has not been elucidated, the knowledge gained in the past six decades together with new advances in precision medicine and molecular diagnostic techniques will allow for the development of more personalized strategies to prevent and treat conditions that are affected by estrogens and other steroid hormones.

Acknowledgments

This work was supported by funding from NIH K01HL133520 (PS), NIH R03HL141618 (PS), Center for Research on Women and Newborn Health (PS), and the American Physiological Society Porter Physiology Development Program (NF).

References

- Acconcia, F., Totta, P., Ogawa, S., Cardillo, I., Inoue, S., Leone, S., et al. (2005). Survival versus apoptotic 17 β -estradiol effect: Role of ER α and ER β activated non-genomic signaling. *Journal of Cellular Physiology*, 203(1), 193–201. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15389627>. <https://doi.org/10.1002/jcp.20219>.
- Allen, E., & Doisy, E. A. (1983). Landmark article Sept 8, 1923. An ovarian hormone. Preliminary report on its localization, extraction and partial purification, and action in test animals. By Edgar Allen and Edward A. Doisy. *JAMA*, 250(19), 2681–2683. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/6355545>.
- Aranda, A., & Pascual, A. (2001). Nuclear hormone receptors and gene expression. *Physiological Reviews*, 81(3), 1269–1304. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11427696>. <https://doi.org/10.1152/physrev.2001.81.3.1269>.
- Aravindakshan, J., Gregory, M., Marcogliese, D. J., Fournier, M., & Cyr, D. G. (2004). Consumption of xenoestrogen-contaminated fish during lactation alters adult male reproductive function. *Toxicological Sciences: An Official Journal of the Society of Toxicology*, 81(1), 179–189. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15159524>. <https://doi.org/10.1093/toxsci/kfh174>.
- Aravindakshan, J., Paquet, V., Gregory, M., Dufresne, J., Fournier, M., Marcogliese, D. J., et al. (2004). Consequences of xenoestrogen exposure on male reproductive function in spottail shiners (*Notropis hudsonius*). *Toxicological Sciences: An Official Journal of the Society of Toxicology*, 78(1), 156–165. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14657511>. <https://doi.org/10.1093/toxsci/kfh042>.
- Arnal, J. F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., et al. (2017). Membrane and nuclear estrogen receptor α actions: From tissue specificity to medical implications. *Physiological Reviews*, 97(3), 1045–1087. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/28539435>. <https://doi.org/10.1152/physrev.00024.2016>.
- Arukwe, A., Celiuș, T., Walther, B. T., & Goksøyr, A. (2000). Effects of xenoestrogen treatment on zona radiata protein and vitellogenin expression in Atlantic salmon (*Salmo salar*). *Aquatic Toxicology*, 49(3), 159–170. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10856602>.
- Bajic, V. B., Tan, S. L., Chong, A., Tang, S., Ström, A., Gustafsson, J. A., et al. (2003). Dragon ERE Finder version 2: A tool for accurate detection and analysis of estrogen response elements in vertebrate genomes. *Nucleic Acids Research*, 31(13), 3605–3607. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12824376>.
- Barakat, R., Oakley, O., Kim, H., Jin, J., & Ko, C. J. (2016). Extra-gonadal sites of estrogen biosynthesis and function. *BMB Reports*, 49(9), 488–496. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/27530684>.
- Barton, M., Filardo, E. J., Lolait, S. J., Thomas, P., Maggiolini, M., & Prossnitz, E. R. (2018). Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. *The Journal of Steroid Biochemistry and Molecular Biology*, 176, 4–15. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/28347854>. <https://doi.org/10.1016/j.jsbmb.2017.03.021>.

- Basu, P., & Maier, C. (2018). Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives. *Biomedicine & Pharmacotherapy*, 107, 1648–1666. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/30257383>. <https://doi.org/10.1016/j.biopha.2018.08.100>.
- Belfiore, C. J., Hawkins, D. E., Wiltbank, M. C., & Niswender, G. D. (1994). Regulation of cytochrome P450_{scc} synthesis and activity in the ovine corpus luteum. *The Journal of Steroid Biochemistry and Molecular Biology*, 51(5–6), 283–290. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7826890>.
- Bennesch, M. A., & Picard, D. (2015). Minireview: Tipping the balance: Ligand-independent activation of steroid receptors. *Molecular Endocrinology*, 29(3), 349–363. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25625619>. <https://doi.org/10.1210/me.2014-1315>.
- Björnström, L., & Sjöberg, M. (2005). Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. *Molecular Endocrinology*, 19(4), 833–842. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15695368>. <https://doi.org/10.1210/me.2004-0486>.
- Blizzard, T. A., Gude, C., Chan, W., Birzin, E. T., Mojena, M., Tudela, C., et al. (2007). Bridged androstenediol analogs as ER-beta selective SERMs. *Bioorganic & Medicinal Chemistry Letters*, 17(10), 2944–2948. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17448656>. <https://doi.org/10.1016/j.bmcl.2006.12.053>.
- Blizzard, T. A., Gude, C., Morgan, J. D., Chan, W., Birzin, E. T., Mojena, M., et al. (2006). Androstenediol analogs as ER-beta-selective SERMs. *Bioorganic & Medicinal Chemistry Letters*, 16(4), 834–838. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16309907>. <https://doi.org/10.1016/j.bmcl.2005.11.014>.
- Blizzard, T. A., Gude, C., Morgan, J. D., Chan, W., Birzin, E. T., Mojena, M., et al. (2007). Androstene-3,5-dienes as ER-beta selective SERMs. *Bioorganic & Medicinal Chemistry Letters*, 17(22), 6295–6298. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17890084>. <https://doi.org/10.1016/j.bmcl.2007.09.001>.
- Boonyaratanakornkit, V. (2011). Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptor. *Steroids*, 76(9), 877–884. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/21354435>. <https://doi.org/10.1016/j.steroids.2011.02.017>.
- Boonyaratanakornkit, V., & Edwards, D. P. (2007). Receptor mechanisms mediating non-genomic actions of sex steroids. *Seminars in Reproductive Medicine*, 25(3), 139–153. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17447204>. <https://doi.org/10.1055/s-2007-973427>.
- Bourdeau, V., Deschênes, J., Métivier, R., Nagai, Y., Nguyen, D., Bretschneider, N., et al. (2004). Genome-wide identification of high-affinity estrogen response elements in human and mouse. *Molecular Endocrinology*, 18(6), 1411–1427. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15001666>. <https://doi.org/10.1210/me.2003-0441>.
- Bourguet, W., Germain, P., & Gronemeyer, H. (2000). Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications. *Trends in Pharmacological Sciences*, 21(10), 381–388. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11050318>.
- Bulun, S. E., Zeitoun, K., Sasano, H., & Simpson, E. R. (1999). Aromatase in aging women. *Seminars in Reproductive Endocrinology*, 17(4), 349–358. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10851574>. <https://doi.org/10.1055/s-2007-1016244>.
- Burns, K. A., & Korach, K. S. (2012). Estrogen receptors and human disease: An update. *Archives of Toxicology*, 86(10), 1491–1504. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/22648069>. <https://doi.org/10.1007/s00204-012-0868-5>.

- Carmeci, C., Thompson, D. A., Ring, H. Z., Francke, U., & Weigel, R. J. (1997). Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. *Genomics*, 45(3), 607–617. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9367686>. <https://doi.org/10.1006/geno.1997.4972>.
- Carr, B. R., MacDonald, P. C., & Simpson, E. R. (1982). The role of lipoproteins in the regulation of progesterone secretion by the human corpus luteum. *Fertility and Sterility*, 38(3), 303–311. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7117556>.
- Carroll, J. S., & Brown, M. (2006). Estrogen receptor target gene: An evolving concept. *Molecular Endocrinology*, 20(8), 1707–1714. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16396959>. <https://doi.org/10.1210/me.2005-0334>.
- Cavalcanti, F. N., Lucas, T. F., Lazari, M. F., & Porto, C. S. (2015). Estrogen receptor ESR1 mediates activation of ERK1/2, CREB, and ELK1 in the corpus of the epididymis. *Journal of Molecular Endocrinology*, 54(3), 339–349. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/26069273>. <https://doi.org/10.1530/JME-15-0086>.
- Chambliss, K. L., & Shaul, P. W. (2002). Rapid activation of endothelial NO synthase by estrogen: Evidence for a steroid receptor fast-action complex (SRFC) in caveolae. *Steroids*, 67(6), 413–419. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11960616>.
- Chambliss, K. L., Yuhanna, I. S., Mineo, C., Liu, P., German, Z., Sherman, T. S., et al. (2000). Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. *Circulation Research*, 87(11), E44–E52. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11090554>.
- Cheng, Z., Rios, G. R., King, C. D., Coffman, B. L., Green, M. D., Mojarrabi, B., et al. (1998). Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. *Toxicological Sciences: An Official Journal of the Society of Toxicology*, 45(1), 52–57. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9848110>. <https://doi.org/10.1006/toxs.1998.2494>.
- Cheskis, B. J., Greger, J., Cooch, N., McNally, C., Mclarney, S., Lam, H. S., et al. (2008). MNAR plays an important role in ERα activation of Src/MAPK and PI3K/Akt signaling pathways. *Steroids*, 73(9–10), 901–905. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18261753>. <https://doi.org/10.1016/j.steroids.2007.12.028>.
- Christin, M. S., Ménard, L., Gendron, A. D., Ruby, S., Cyr, D., Marcogliese, D. J., et al. (2004). Effects of agricultural pesticides on the immune system of *Xenopus laevis* and *Rana pipiens*. *Aquatic Toxicology*, 67(1), 33–43. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15019249>. <https://doi.org/10.1016/j.aquatox.2003.11.007>.
- Coelingh Bennink, F., Holinka, C. F., Visser, M., & Coelingh Bennink, H. J. (2008). Maternal and fetal estetrol levels during pregnancy. *Climacteric: The Journal of the International Menopause Society*, 11(Suppl. 1), 69–72. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18464026>. <https://doi.org/10.1080/13697130802056321>.
- de Leeuw, R., Neeffes, J., & Michalides, R. (2011). A role for estrogen receptor phosphorylation in the resistance to tamoxifen. *International Journal of Breast Cancer*, 2011, 232435. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/22295213>. <https://doi.org/10.4061/2011/232435>.
- Dos Santos, E. G., Dieudonne, M. N., Pecquery, R., Le Moal, V., Giudicelli, Y., & Lacasa, D. (2002). Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. *Endocrinology*, 143(3), 930–940. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11861515>. <https://doi.org/10.1210/endo.143.3.8678>.
- Enmark, E., Peltö-Huikko, M., Grandien, K., Lagercrantz, S., Lagercrantz, J., Fried, G., et al. (1997). Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. *The Journal of Clinical Endocrinology and Metabolism*, 82(12), 4258–4265. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9398750>. <https://doi.org/10.1210/jcem.82.12.4470>.

- Farooq, A. (2015). Structural and functional diversity of estrogen receptor ligands. *Current Topics in Medicinal Chemistry*, 15(14), 1372–1384. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25866274>.
- Feng, Y., & Gregor, P. (1997). Cloning of a novel member of the G protein-coupled receptor family related to peptide receptors. *Biochemical and Biophysical Research Communications*, 231(3), 651–654. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9070864>. <https://doi.org/10.1006/bbrc.1997.6161>.
- Filardo, E. J., Quinn, J. A., Bland, K. I., & Frackelton, A. R. (2000). Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. *Molecular Endocrinology*, 14(10), 1649–1660. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11043579>. <https://doi.org/10.1210/mend.14.10.0532>.
- Filardo, E., Quinn, J., Pang, Y., Graeber, C., Shaw, S., Dong, J., et al. (2007). Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. *Endocrinology*, 148(7), 3236–3245. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17379646>. <https://doi.org/10.1210/en.2006-1605>.
- Filardo, E. J., & Thomas, P. (2012). Minireview: G protein-coupled estrogen receptor-1, GPER-1: Its mechanism of action and role in female reproductive cancer, renal and vascular physiology. *Endocrinology*, 153(7), 2953–2962. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/22495674>. <https://doi.org/10.1210/en.2012-1061>.
- Fox, E. M., Andrade, J., & Shupnik, M. A. (2009). Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways. *Steroids*, 74(7), 622–627. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18996136>. <https://doi.org/10.1016/j.steroids.2008.10.014>.
- Fujimoto, N., Honda, H., & Kitamura, S. (2004). Effects of environmental estrogenic chemicals on AP1 mediated transcription with estrogen receptors alpha and beta. *The Journal of Steroid Biochemistry and Molecular Biology*, 88(1), 53–59. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15026083>. <https://doi.org/10.1016/j.jsbmb.2003.10.006>.
- Furth, P. A. (2014). STAT signaling in different breast cancer sub-types. *Molecular and Cellular Endocrinology*, 382(1), 612–615. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23562422>. <https://doi.org/10.1016/j.mce.2013.03.023>.
- Galien, R., & Garcia, T. (1997). Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. *Nucleic Acids Research*, 25(12), 2424–2429. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9171095>.
- Garbacz, W. G., Jiang, M., & Xie, W. (2017). Sex-dependent role of estrogen sulfotransferase and steroid sulfatase in metabolic homeostasis. *Advances in Experimental Medicine and Biology*, 1043, 455–469. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29224107>. https://doi.org/10.1007/978-3-319-70178-3_21.
- Gaub, M. P., Bellard, M., Scheuer, I., Chambon, P., & Sassone-Corsi, P. (1990). Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. *Cell*, 63(6), 1267–1276. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/2124518>.
- Gennari, L., Merlotti, D., Valleggi, F., Martini, G., & Nuti, R. (2007). Selective estrogen receptor modulators for postmenopausal osteoporosis: Current state of development. *Drugs & Aging*, 24(5), 361–379. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17503894>. <https://doi.org/10.2165/00002512-200724050-00002>.
- Golden, R. J., Noller, K. L., Titus-Ernstoff, L., Kaufman, R. H., Mittendorf, R., Stillman, R., et al. (1998). Environmental endocrine modulators and human health: An assessment of the biological evidence. *Critical Reviews in Toxicology*, 28(2), 109–227. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9557209>. <https://doi.org/10.1080/10408449891344191>.

- Gosden, J. R., Middleton, P. G., & Rout, D. (1986). Localization of the human oestrogen receptor gene to chromosome 6q24—q27 by in situ hybridization. *Cytogenetics and Cell Genetics*, 43(3–4), 218–220. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/3802924>. <https://doi.org/10.1159/000132325>.
- Göttlicher, M., Heck, S., & Herrlich, P. (1998). Transcriptional cross-talk, the second mode of steroid hormone receptor action. *Journal of Molecular Medicine (Berlin)*, 76(7), 480–489. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9660166>.
- Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J. M., Argos, P., et al. (1986). Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. *Nature*, 320(6058), 134–139. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/3754034>. <https://doi.org/10.1038/320134a0>.
- Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., & Shine, J. (1986). Sequence and expression of human estrogen receptor complementary DNA. *Science (New York, N.Y.)*, 231(4742), 1150–1154. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/3753802>.
- Gruber, C. J., Tschugguel, W., Schneeberger, C., & Huber, J. C. (2002). Production and actions of estrogens. *The New England Journal of Medicine*, 346(5), 340–352. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11821512>. <https://doi.org/10.1056/NEJMra000471>.
- Gu, Y., Chen, T., López, E., Wu, W., Wang, X., Cao, J., et al. (2014). The therapeutic target of estrogen receptor- α 36 in estrogen-dependent tumors. *Journal of Translational Medicine*, 12, 16. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/24447535>. <https://doi.org/10.1186/1479-5876-12-16>.
- Gu, Q., & Moss, R. L. (1996). 17 beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. *The Journal of Neuroscience*, 16(11), 3620–3629. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8642406>.
- Hall, J. M., McDonnell, D. P., & Korach, K. S. (2002). Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. *Molecular Endocrinology*, 16(3), 469–486. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11875105>. <https://doi.org/10.1210/mend.16.3.0814>.
- Hamilton, K. J., Hewitt, S. C., Arao, Y., & Korach, K. S. (2017). Estrogen hormone biology. *Current Topics in Developmental Biology*, 125, 109–146. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/28527569>. <https://doi.org/10.1016/bs.ctdb.2016.12.005>.
- Han, S. J., Lonard, D. M., & O'Malley, B. W. (2009). Multi-modulation of nuclear receptor coactivators through posttranslational modifications. *Trends in Endocrinology and Metabolism*, 20(1), 8–15. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/19019695>. <https://doi.org/10.1016/j.tem.2008.10.001>.
- Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997). A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature*, 387(6634), 733–736. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9192902>. <https://doi.org/10.1038/42750>.
- Holinka, C. F., Diczfalusy, E., & Coelingh Bennink, H. J. (2008). Estetrol: A unique steroid in human pregnancy. *The Journal of Steroid Biochemistry and Molecular Biology*, 110(1–2), 138–143. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18462934>. <https://doi.org/10.1016/j.jsbmb.2008.03.027>.
- Hu, R., Hilakivi-Clarke, L., & Clarke, R. (2015). Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). *Oncology Letters*, 9(4), 1495–1501. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25788989>. <https://doi.org/10.3892/ol.2015.2962>.
- Hu, X., & Lazar, M. A. (1999). The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. *Nature*, 402(6757), 93–96. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10573424>. <https://doi.org/10.1038/47069>.

- Iorga, A., Cunningham, C. M., Moazeni, S., Ruffenach, G., Umar, S., & Eghbali, M. (2017). The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. *Biology of Sex Differences*, 8(1), 33. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29065927>. <https://doi.org/10.1186/s13293-017-0152-8>.
- ITTRICH, G., & NEUMANN, H. (1963). PARTICIPATION OF THE FETUS IN ESTROGEN METABOLISM OF THE MOTHER. *Ceskoslovenská Gynekologie*, 28, 454–456. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14091393>.
- Jensen, E. V., Desombre, E. R., Kawashima, T., Suzuki, T., Kyser, K., & Jungblut, P. W. (1967). Estrogen-binding substances of target tissues. *Science (New York, N.Y.)*, 158(3800), 529–530. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17749092>. <https://doi.org/10.1126/science.158.3800.529-c>.
- Jensen, E. V., Suzuki, T., Kawashima, T., Stumpf, W. E., Jungblut, P. W., & DeSombre, E. R. (1968). A two-step mechanism for the interaction of estradiol with rat uterus. *Proceedings of the National Academy of Sciences of the United States of America*, 59(2), 632–638. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/5238991>.
- Kalaitzidis, D., & Gilmore, T. D. (2005). Transcription factor cross-talk: The estrogen receptor and NF-kappaB. *Trends in Endocrinology and Metabolism*, 16(2), 46–52. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15734144>. <https://doi.org/10.1016/j.tem.2005.01.004>.
- Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., et al. (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science (New York, N.Y.)*, 270(5241), 1491–1494. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7491495>.
- Khan, D., & Ansar Ahmed, S. (2015). The immune system is a natural target For estrogen action: Opposing effects of estrogen in two prototypical autoimmune diseases. *Frontiers in Immunology*, 6, 635. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/26779182>. <https://doi.org/10.3389/fimmu.2015.00635>.
- Klinge, C. M. (2001). Estrogen receptor interaction with estrogen response elements. *Nucleic Acids Research*, 29(14), 2905–2919. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11452016>.
- Koos, R. D. (2011). Minireview: Putting physiology back into estrogens' mechanism of action. *Endocrinology*, 152(12), 4481–4488. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/21952239>. <https://doi.org/10.1210/en.2011-1449>.
- Kousteni, S., Han, L., Chen, J. R., Almeida, M., Plotkin, L. I., Bellido, T., et al. (2003). Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. *The Journal of Clinical Investigation*, 111(11), 1651–1664. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12782668>. <https://doi.org/10.1172/JCI17261>.
- Kuiper, G. G., Enmark, E., Peltö-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996). Cloning of a novel receptor expressed in rat prostate and ovary. *Proceedings of the National Academy of Sciences of the United States of America*, 93(12), 5925–5930. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8650195>.
- Kuiper, G. G., Lemmen, J. G., Carlsson, B., Corton, J. C., Safe, S. H., van der Saag, P. T., et al. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology*, 139(10), 4252–4263. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9751507>. <https://doi.org/10.1210/endo.139.10.6216>.
- Kumar, R., Zakharov, M. N., Khan, S. H., Miki, R., Jang, H., Toraldo, G., et al. (2011). The dynamic structure of the estrogen receptor. *Journal of Amino Acids*, 2011, 812540. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/22312471>. <https://doi.org/10.4061/2011/812540>.

- Kvingedal, A. M., & Smeland, E. B. (1997). A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. *FEBS Letters*, 407(1), 59–62. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9141481>.
- Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., et al. (1998). DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging. *Steroids*, 63(5–6), 322–328. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9618795>.
- Lakhani, N. J., Venitz, J., Figg, W. D., & Sparreboom, A. (2003). Pharmacogenetics of estrogen metabolism and transport in relation to cancer. *Current Drug Metabolism*, 4(6), 505–513. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14683478>.
- Laliotis, A., Vrekoussis, T., Kafousi, M., Sanidas, E., Askoxilakis, J., Melissas, J., et al. (2013). Immunohistochemical study of pElk-1 expression in human breast cancer: Association with breast cancer biologic profile and clinicopathologic features. *Breast*, 22(1), 89–95. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23127278>. <https://doi.org/10.1016/j.breast.2012.09.013>.
- Le Dily, F., & Beato, M. (2018). Signaling by steroid hormones in the 3D nuclear space. *International Journal of Molecular Sciences*, 19(2), 306. <https://doi.org/10.3390/ijms19020306> Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29360755>.
- Li, C., Briggs, M. R., Ahlborn, T. E., Kraemer, F. B., & Liu, J. (2001). Requirement of Sp1 and estrogen receptor alpha interaction in 17beta-estradiol-mediated transcriptional activation of the low density lipoprotein receptor gene expression. *Endocrinology*, 142(4), 1546–1553. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11250935>. <https://doi.org/10.1210/endo.142.4.8096>.
- Li, L., Haynes, M. P., & Bender, J. R. (2003). Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, 100(8), 4807–4812. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12682286>. <https://doi.org/10.1073/pnas.0831079100>.
- Li, L., Hisamoto, K., Kim, K. H., Haynes, M. P., Bauer, P. M., Sanjay, A., et al. (2007). Variant estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. *Proceedings of the National Academy of Sciences of the United States of America*, 104(42), 16468–16473. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17921256>. <https://doi.org/10.1073/pnas.0704315104>.
- Li, Y., Wang, J. P., Santen, R. J., Kim, T. H., Park, H., Fan, P., et al. (2010). Estrogen stimulation of cell migration involves multiple signaling pathway interactions. *Endocrinology*, 151(11), 5146–5156. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/20861240>. <https://doi.org/10.1210/en.2009-1506>.
- Liang, J., & Shang, Y. (2013). Estrogen and cancer. *Annual Review of Physiology*, 75, 225–240. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23043248>. <https://doi.org/10.1146/annurev-physiol-030212-183708>.
- Liu, M. M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., et al. (2002). Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. *The Journal of Biological Chemistry*, 277(27), 24353–24360. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11986316>. <https://doi.org/10.1074/jbc.M201829200>.
- Lonard, D. M., & O'Malley, B. W. (2006). The expanding cosmos of nuclear receptor coactivators. *Cell*, 125(3), 411–414. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16678083>. <https://doi.org/10.1016/j.cell.2006.04.021>.
- Lonard, D. M., & O'malley, B. W. (2007). Nuclear receptor coregulators: Judges, juries, and executioners of cellular regulation. *Molecular Cell*, 27(5), 691–700. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17803935>. <https://doi.org/10.1016/j.molcel.2007.08.012>.

- Lösel, R., & Wehling, M. (2003). Nongenomic actions of steroid hormones. *Nature Reviews. Molecular Cell Biology*, 4(1), 46–56.
- Loven, M. A., Wood, J. R., & Nardulli, A. M. (2001). Interaction of estrogen receptors alpha and beta with estrogen response elements. *Molecular and Cellular Endocrinology*, 181(1–2), 151–163. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11476949>.
- Maggi, A. (2011). Liganded and unliganded activation of estrogen receptor and hormone replacement therapies. *Biochimica et Biophysica Acta*, 1812(8), 1054–1060. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/21605666>. <https://doi.org/10.1016/j.bbadis.2011.05.001>.
- Manas, E. S., Xu, Z. B., Unwalla, R. J., & Somers, W. S. (2004). Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. *Structure*, 12(12), 2197–2207. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15576033>. <https://doi.org/10.1016/j.str.2004.09.015>.
- Manavathi, B., Samanthapudi, V. S., & Gajulapalli, V. N. (2014). Estrogen receptor coregulators and pioneer factors: The orchestrators of mammary gland cell fate and development. *Frontiers in Cell and Development Biology*, 2, 34. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25364741>. <https://doi.org/10.3389/fcell.2014.00034>.
- Marino, M., Acconcia, F., Bresciani, F., Weisz, A., & Trentalance, A. (2002). Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells. *Molecular Biology of the Cell*, 13(10), 3720–3729. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12388769>. <https://doi.org/10.1091/mbc.e02-03-0153>.
- Marino, M., Acconcia, F., & Trentalance, A. (2003). Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. *Molecular Biology of the Cell*, 14(6), 2583–2591. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12808053>. <https://doi.org/10.1091/mbc.e02-09-0621>.
- Marino, M., Galluzzo, P., & Ascenzi, P. (2006). Estrogen signaling multiple pathways to impact gene transcription. *Current Genomics*, 7(8), 497–508. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18369406>.
- Marino, M., Pallottini, V., & Trentalance, A. (1998). Estrogens cause rapid activation of IP3-PKC-alpha signal transduction pathway in HEPG2 cells. *Biochemical and Biophysical Research Communications*, 245(1), 254–258. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9535818>. <https://doi.org/10.1006/bbrc.1998.8413>.
- Martinkovich, S., Shah, D., Planey, S. L., & Arnott, J. A. (2014). Selective estrogen receptor modulators: Tissue specificity and clinical utility. *Clinical Interventions in Aging*, 9, 1437–1452. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25210448>. <https://doi.org/10.2147/CIA.S66690>.
- Matthews, J., & Gustafsson, J. A. (2003). Estrogen signaling: A subtle balance between ER alpha and ER beta. *Molecular Interventions*, 3(5), 281–292. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14993442>. <https://doi.org/10.1124/mi.3.5.281>.
- Maximov, P. Y., Lee, T. M., & Jordan, V. C. (2013). The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. *Current Clinical Pharmacology*, 8(2), 135–155. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23062036>.
- Mersereau, J. E., Levy, N., Staub, R. E., Baggett, S., Zogovic, T., Zogric, T., et al. (2008). Lignixigenin is a plant-derived highly selective estrogen receptor beta agonist. *Molecular and Cellular Endocrinology*, 283(1–2), 49–57. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18177995>. <https://doi.org/10.1016/j.mce.2007.11.020>.
- Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., et al. (1996). Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. *The EMBO Journal*, 15(6), 1292–1300. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8635462>.

- Miller, W. L. (2017). Steroidogenesis: Unanswered Questions. *Trends in Endocrinology and Metabolism*, 28(11), 771–793. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29031608>. <https://doi.org/10.1016/j.tem.2017.09.002>.
- Miller, W. L., & Strauss, J. F. (1999). Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. *The Journal of Steroid Biochemistry and Molecular Biology*, 69(1–6), 131–141. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10418987>.
- Mishra, S. K., Balasenthil, S., Nguyen, D., & Vadlamudi, R. K. (2004). Cloning and functional characterization of PELP1/MNAR promoter. *Gene*, 330, 115–122. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15087130>. <https://doi.org/10.1016/j.gene.2004.01.011>.
- Molina, L., Figueroa, C. D., Bhoola, K. D., & Ehrenfeld, P. (2017). GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: Therapeutic coupling to breast cancer. *Expert Opinion on Therapeutic Targets*, 21(8), 755–766. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/28671018>. <https://doi.org/10.1080/14728222.2017.1350264>.
- Nelson, L. R., & Bulun, S. E. (2001). Estrogen production and action. *Journal of the American Academy of Dermatology*, 45(3 Suppl), S116–S124. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11511861>.
- Nilsson, S., Kuiper, G., & Gustafsson, J. A. (1998). ERbeta: A novel estrogen receptor offers the potential for new drug development. *Trends in Endocrinology and Metabolism*, 9(10), 387–395. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18406312>.
- Nilsson, S., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., et al. (2001). Mechanisms of estrogen action. *Physiological Reviews*, 81(4), 1535–1565. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11581496>. <https://doi.org/10.1152/physrev.2001.81.4.1535>.
- O'Dowd, B. F., Nguyen, T., Marchese, A., Cheng, R., Lynch, K. R., Heng, H. H., et al. (1998). Discovery of three novel G-protein-coupled receptor genes. *Genomics*, 47(2), 310–313. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9479505>. <https://doi.org/10.1006/geno.1998.5095>.
- O'Lone, R., Frith, M. C., Karlsson, E. K., & Hansen, U. (2004). Genomic targets of nuclear estrogen receptors. *Molecular Endocrinology*, 18(8), 1859–1875. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15031323>. <https://doi.org/10.1210/me.2003-0044>.
- O'Malley, B. W. (2005). A life-long search for the molecular pathways of steroid hormone action. *Molecular Endocrinology*, 19(6), 1402–1411. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15914709>. <https://doi.org/10.1210/me.2004-0480>.
- O'Malley, B. W., & McKenna, N. J. (2008). Coactivators and corepressors: What's in a name? *Molecular Endocrinology*, 22(10), 2213–2214. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18701638>. <https://doi.org/10.1210/me.2008-0201>.
- Oñate, S. A., Tsai, S. Y., Tsai, M. J., & O'Malley, B. W. (1995). Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. *Science (New York, N.Y.)*, 270(5240), 1354–1357. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7481822>.
- Owman, C., Blay, P., Nilsson, C., & Lolait, S. J. (1996). Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues. *Biochemical and Biophysical Research Communications*, 228(2), 285–292. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8920907>. <https://doi.org/10.1006/bbrc.1996.1654>.
- Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. *Nature*, 401(6748), 82–85. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10485710>. <https://doi.org/10.1038/43466>.

- Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., et al. (1997). Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. *Science (New York, N.Y.)*, 277(5331), 1508–1510. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9278514>.
- Papapetropoulos, A. (2007). A ginseng-derived oestrogen receptor beta (ERbeta) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis. *British Journal of Pharmacology*, 152(2), 172–174. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17603551>. <https://doi.org/10.1038/sj.bjp.0707360>.
- Picotto, G., Massheimer, V., & Boland, R. (1996). Acute stimulation of intestinal cell calcium influx induced by 17 beta-estradiol via the cAMP messenger system. *Molecular and Cellular Endocrinology*, 119(2), 129–134. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8807632>.
- Piu, F., Aronheim, A., Katz, S., & Karin, M. (2001). AP-1 repressor protein JDP-2: Inhibition of UV-mediated apoptosis through p53 down-regulation. *Molecular and Cellular Biology*, 21(9), 3012–3024. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11287607>. <https://doi.org/10.1128/MCB.21.9.3012-3024.2001>.
- Prossnitz, E. R., & Barton, M. (2011). The G-protein-coupled estrogen receptor GPER in health and disease. *Nature Reviews. Endocrinology*, 7(12), 715–726. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/21844907>. <https://doi.org/10.1038/nrendo.2011.122>.
- Prossnitz, E. R., & Barton, M. (2014). Estrogen biology: New insights into GPER function and clinical opportunities. *Molecular and Cellular Endocrinology*, 389(1–2), 71–83. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/24530924>. <https://doi.org/10.1016/j.mce.2014.02.002>.
- Purohit, A., & Reed, M. J. (2002). Regulation of estrogen synthesis in postmenopausal women. *Steroids*, 67(12), 979–983. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12398994>.
- Purohit, A., Tutill, H. J., Day, J. M., Chander, S. K., Lawrence, H. R., Allan, G. M., et al. (2006). The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. *Molecular and Cellular Endocrinology*, 248(1–2), 199–203. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16414180>. <https://doi.org/10.1016/j.mce.2005.12.003>.
- Razandi, M., Pedram, A., Merchenthaler, I., Greene, G. L., & Levin, E. R. (2004). Plasma membrane estrogen receptors exist and functions as dimers. *Molecular Endocrinology*, 18(12), 2854–2865. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15231873>. <https://doi.org/10.1210/me.2004-0115>.
- Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005). A transmembrane intracellular estrogen receptor mediates rapid cell signaling. *Science (New York, N.Y.)*, 307(5715), 1625–1630. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15705806>. <https://doi.org/10.1126/science.1106943>.
- Romano, S. N., & Gorelick, D. A. (2018). Crosstalk between nuclear and G protein-coupled estrogen receptors. *General and Comparative Endocrinology*, 261, 190–197. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/28450143>. <https://doi.org/10.1016/j.ygcen.2017.04.013>.
- Romashkova, J. A., & Makarov, S. S. (1999). NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. *Nature*, 401(6748), 86–90. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10485711>. <https://doi.org/10.1038/43474>.
- RYAN, K. J. (1959). Biological aromatization of steroids. *The Journal of Biological Chemistry*, 234(2), 268–272. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/13630892>.
- Samavat, H., & Kurzer, M. S. (2015). Estrogen metabolism and breast cancer. *Cancer Letters*, 356(2 Pt. A), 231–243. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/24784887>. <https://doi.org/10.1016/j.canlet.2014.04.018>.

- Sausville, E., Carney, D., & Battey, J. (1985). The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. *The Journal of Biological Chemistry*, 260(18), 10236–10241. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/2991279>.
- Scheidereit, C., Krauter, P., von der Ahe, D., Janich, S., Rabenau, O., Cato, A. C., et al. (1986). Mechanism of gene regulation by steroid hormones. *Journal of Steroid Biochemistry*, 24(1), 19–24. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/3009974>.
- Schulster, M., Bernie, A. M., & Ramasamy, R. (2016). The role of estradiol in male reproductive function. *Asian Journal of Andrology*, 18(3), 435–440. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/26908066>. <https://doi.org/10.4103/1008-682X.173932>.
- Schwabe, J. W., & Teichmann, S. A. (2004). Nuclear receptors: The evolution of diversity. *Science's STKE: Signal Transduction Knowledge Environment*, 2004(217), pe4. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14747695>. <https://doi.org/10.1126/stke.2172004pe4>.
- Shang, Y., & Brown, M. (2002). Molecular determinants for the tissue specificity of SERMs. *Science (New York, N.Y.)*, 295(5564), 2465–2468. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11923541>. <https://doi.org/10.1126/science.1068537>.
- Sharma, G., & Prossnitz, E. R. (2016). GPER/GPR30 Knockout Mice: Effects of GPER on Metabolism. *Methods in Molecular Biology*, 1366, 489–502. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/26585159>. https://doi.org/10.1007/978-1-4939-3127-9_38.
- Shaul, P. W., & Anderson, R. G. (1998). Role of plasmalemmal caveolae in signal transduction. *The American Journal of Physiology*, 275(5 Pt. 1), L843–L851. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9815100>.
- Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., et al. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell*, 95(7), 927–937. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9875847>.
- Silva, E., Kabil, A., & Kortenkamp, A. (2010). Cross-talk between non-genomic and genomic signalling pathways—Distinct effect profiles of environmental estrogens. *Toxicology and Applied Pharmacology*, 245(2), 160–170. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/20206645>. <https://doi.org/10.1016/j.taap.2010.02.015>.
- Simpson, E. R. (2003). Sources of estrogen and their importance. *The Journal of Steroid Biochemistry and Molecular Biology*, 86(3–5), 225–230. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14623515>.
- Simpson, E. R., Clyne, C., Rubin, G., Boon, W. C., Robertson, K., Britt, K., et al. (2002). Aromatase—A brief overview. *Annual Review of Physiology*, 64, 93–127. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11826265>. <https://doi.org/10.1146/annurev.physiol.64.081601.142703>.
- Simpson, E. R., Misso, M., Hewitt, K. N., Hill, R. A., Boon, W. C., Jones, M. E., et al. (2005). Estrogen—The good, the bad, and the unexpected. *Endocrine Reviews*, 26(3), 322–330. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15817672>. <https://doi.org/10.1210/er.2004-0020>.
- Smith, C. L., & O'Malley, B. W. (2004). Coregulator function: A key to understanding tissue specificity of selective receptor modulators. *Endocrine Reviews*, 25(1), 45–71. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14769827>. <https://doi.org/10.1210/er.2003-0023>.
- Song, R. X., Chen, Y., Zhang, Z., Bao, Y., Yue, W., Wang, J. P., et al. (2010). Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. *The Journal of Steroid Biochemistry and Molecular Biology*, 118(4–5), 219–230. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/19815064>. <https://doi.org/10.1016/j.jsbmb.2009.09.018>.

- Song, R. X., Zhang, Z., Chen, Y., Bao, Y., & Santen, R. J. (2007). Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. *Endocrinology*, 148(8), 4091–4101. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17525128>. <https://doi.org/10.1210/en.2007-0240>.
- Song, R. X., Zhang, Z., & Santen, R. J. (2005). Estrogen rapid action via protein complex formation involving ERalpha and Src. *Trends in Endocrinology and Metabolism*, 16(8), 347–353. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16126407>. <https://doi.org/10.1016/j.tem.2005.06.010>.
- Stoica, A., Katzenellenbogen, B. S., & Martin, M. B. (2000). Activation of estrogen receptor-alpha by the heavy metal cadmium. *Molecular Endocrinology*, 14(4), 545–553. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10770491>. <https://doi.org/10.1210/mend.14.4.0441>.
- Stoica, A., Pentecost, E., & Martin, M. B. (2000a). Effects of arsenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells. *Endocrinology*, 141(10), 3595–3602. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11014213>. <https://doi.org/10.1210/endo.141.10.7704>.
- Stoica, A., Pentecost, E., & Martin, M. B. (2000b). Effects of selenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells. *Journal of Cellular Biochemistry*, 79(2), 282–292. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10967555>.
- Sun, G., Porter, W., & Safe, S. (1998). Estrogen-induced retinoic acid receptor alpha 1 gene expression: Role of estrogen receptor-Sp1 complex. *Molecular Endocrinology*, 12(6), 882–890. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9626663>. <https://doi.org/10.1210/mend.12.6.0125>.
- Takada, Y., Kato, C., Kondo, S., Korenaga, R., & Ando, J. (1997). Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. *Biochemical and Biophysical Research Communications*, 240(3), 737–741. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9398636>. <https://doi.org/10.1006/bbrc.1997.7734>.
- Thomas, P., Pang, Y., Filardo, E. J., & Dong, J. (2005). Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. *Endocrinology*, 146(2), 624–632. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15539556>. <https://doi.org/10.1210/en.2004-1064>.
- Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E., et al. (1989). The human estrogen receptor has two independent nonacidic transcriptional activation functions. *Cell*, 59(3), 477–487. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/2805068>.
- Truss, M., & Beato, M. (1993). Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. *Endocrine Reviews*, 14(4), 459–479. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8223341>. <https://doi.org/10.1210/edrv-14-4-459>.
- Tsuchiya, Y., Nakajima, M., & Yokoi, T. (2005). Cytochrome P450-mediated metabolism of estrogens and its regulation in human. *Cancer Letters*, 227(2), 115–124. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16112414>. <https://doi.org/10.1016/j.canlet.2004.10.007>.
- Turner, J. V., Agatonovic-Kustrin, S., & Glass, B. D. (2007). Molecular aspects of phytoestrogen selective binding at estrogen receptors. *Journal of Pharmaceutical Sciences*, 96(8), 1879–1885. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17518366>. <https://doi.org/10.1002/jps.20987>.
- Vajda, A. M., Barber, L. B., Gray, J. L., Lopez, E. M., Woodling, J. D., & Norris, D. O. (2008). Reproductive disruption in fish downstream from an estrogenic wastewater effluent. *Environmental Science & Technology*, 42(9), 3407–3414. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18522126>.

- Voogt, J. L. (1978). Control of hormone release during lactation. *Clinics in Obstetrics and Gynaecology*, 5(2), 435–455. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/361330>.
- Vrtačnik, P., Ostanek, B., Mencej-Bedrač, S., & Marc, J. (2014). The many faces of estrogen signaling. *Biochemica Medica*, 24(3), 329–342. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25351351>. [10.11613/BM.2014.035](https://doi.org/10.11613/BM.2014.035).
- Wärnmark, A., Treuter, E., Gustafsson, J. A., Hubbard, R. E., Brzozowski, A. M., & Pike, A. C. (2002). Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. *The Journal of Biological Chemistry*, 277(24), 21862–21868. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11937504>. <https://doi.org/10.1074/jbc.M200764200>.
- Watson, C. S., Jeng, Y. J., & Kochukov, M. Y. (2008). Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. *The FASEB Journal*, 22(9), 3328–3336. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18541692>. <https://doi.org/10.1096/fj.08-107672>.
- Watters, J., Campbell, J., Cunningham, M., Krebs, E., & Dorsa, D. (1997). Rapid membrane effects of steroids in neuroblastoma cells: Effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. *Endocrinology*, 138(9), 4030–4033.
- Williams, D. E., Lech, J. J., & Buhler, D. R. (1998). Xenobiotics and xenoestrogens in fish: Modulation of cytochrome P450 and carcinogenesis. *Mutation Research*, 399(2), 179–192. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9672659>.
- Wilson, R., Eriksson, G., & Diczfalusy, E. (1964). Oestriol metabolism in pregnant women. *Acta Endocrinologica*, 46, 525–543. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14202469>.
- Yaşar, P., Ayaz, G., User, S. D., Güpür, G., & Muyan, M. (2017). Molecular mechanism of estrogen-estrogen receptor signaling. *Reproductive Medicine and Biology*, 16(1), 4–20. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29259445>. <https://doi.org/10.1002/rmb2.12006>.
- Yi, P., Driscoll, M. D., Huang, J., Bhagat, S., Hilf, R., Bambara, R. A., et al. (2002). The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ER alpha and ER beta. *Molecular Endocrinology*, 16(4), 674–693. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11923465>. <https://doi.org/10.1210/mend.16.4.0810>.